What is the average price target for LIFEMD INC (LFMD) stock?
14 analysts have analysed LFMD and the average price target is 9.44 USD. This implies a price increase of 137.06% is expected in the next year compared to the current price of 3.98.
NASDAQ:LFMD • US53216B1044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LIFEMD INC (LFMD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | Freedom Capital Markets | Maintains | Buy -> Buy |
| 2026-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-10 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-19 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-11-19 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-11-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-11-18 | BTIG | Maintains | Buy -> Buy |
| 2025-11-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | Lake Street | Maintains | Buy -> Buy |
| 2025-08-06 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-10 | Lake Street | Maintains | Buy -> Buy |
| 2025-04-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-12-10 | Lake Street | Initiate | Buy |
| 2024-12-04 | Mizuho | Initiate | Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 119M 28.09% | 152.547M 28.19% | 212.454M 39.27% | 241.45M 13.65% | 228.51M -5.36% | 268.87M 17.66% | 237.56M -11.65% | |
| EBITDA YoY % growth | -30.83M 42.30% | -7.889M 74.41% | -6.653M 15.67% | 25.476M 482.91% | 15.225M -40.24% | 32.64M 114.38% | 40.8M 25.00% | |
| EBIT YoY % growth | -34.6M 36.28% | -14.489M 58.12% | -16.145M -11.42% | -2.835M 82.44% | -6.282M -121.61% | 4.177M 166.49% | 4.08M -2.32% | |
| Operating Margin | -29.08% | -9.50% | -7.60% | -1.17% | -2.75% | 1.55% | 1.72% | |
| EPS YoY % growth | -1.57 30.84% | -0.70 55.41% | -0.54 22.86% | -0.21 70.37% | -0.06 60.16% | 0.23 462.67% | -0.02 -108.82% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 -834.40% | -0.04 25.20% | -0.02 67.94% | 0.00 108.49% | 0.18 350.00% | 0.18 509.09% | 0.18 918.18% | 0.20 5,906.01% |
| Revenue Q2Q % growth | 51.567M -21.51% | 54.803M -11.92% | 58.368M -3.00% | 64.55M 37.73% | 70.976M 37.64% | 73.444M 34.01% | 73.674M 26.22% | 81.876M 26.84% |
| EBITDA Q2Q % growth | 4.574M -12.04% | 4.898M 7.10% | 5.989M -7.90% | 8.698M 136.29% | 8.082M 76.69% | 9.104M 85.87% | 10.275M 71.56% | 13.727M 57.82% |
| EBIT Q2Q % growth | -2.465M -196.94% | -2.261M -149.36% | -1.401M 28.84% | 1.059M 139.40% | 4.098M 266.25% | 3.918M 273.27% | 4.204M 400.01% | 4.741M 347.69% |
All data in USD
14 analysts have analysed LFMD and the average price target is 9.44 USD. This implies a price increase of 137.06% is expected in the next year compared to the current price of 3.98.
LIFEMD INC (LFMD) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of LIFEMD INC (LFMD) is -0.07 USD and the consensus revenue estimate is 51.57M USD.
The number of analysts covering LIFEMD INC (LFMD) is 14.